Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

@article{Albain2009AdjuvantCA,
  title={Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial},
  author={Kathy S. Albain and William Eric Barlow and Peter Marcus Ravdin and William Blair Farrar and Gary Von Burton and Steven J Ketchel and Charles D Cobau and Ellis Glenn Levine and James N. Ingle and Kathleen I. Pritchard and Allen S. Lichter and Daniel J Schneider and Martin D. Abeloff and I. H. C. Henderson and Hyman Bernard Muss and Stephanie J. Green and Danika L. Lew and Robert B. Livingston and Silvana Martino and Charles Osborne},
  journal={The Lancet},
  year={2009},
  volume={374},
  pages={2055-2063}
}
BACKGROUND Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and whether tamoxifen should be given concurrently or after chemotherapy. METHODS We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease… CONTINUE READING
80 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Eff ects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 - year survival : an overview of the randomised trials

  • JM Bull, DC Tormey, SH Li
  • Lancet
  • 2005

A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in stage II breast cancer

  • MR Sertoli, P Pronzato, M Venturini
  • ASCO Annual Meeting; Orlando, FL,
  • 2002

Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial

  • KS Albain, SJ Green, PM Ravdin
  • ASCO Annual Meeting; Orlando, FL,
  • 2002

NIH consensus development conference statement : adjuvant therapy for breast cancer , November 1 – 3 , 2000

  • A Goldhirsch, JH Glick, RD Gelber, AS Coates, B Thurlimann, Senn H-J
  • J Natl Cancer Inst
  • 2001

Randomized trial of intensive cyclophosphamide , methotrexate and fl uorouracil in premenopausal women with node - positive breast cancer . National Cancer Institute of Canada Clinical Trials Group

  • M Perloff, L Norton, AH Korzun
  • J Clin Oncol
  • 1998

Similar Papers

Loading similar papers…